Search

Filler injection has become an extremely popular method for facial skin rejuvenation, including the periorbital area. In the recent years, new polynucleotide (PN)-containing filler products have been used for esthetic purposes. We aimed to investigate the efficacy and safety of PN filler injection in the periorbital area. A total of 27 subjects were enrolled in this randomized, pair-matched, and active-controlled study. Each subject received filler injections thrice with two-week intervals, with a PN filler injection on one side and a non-crosslinked hyaluronic acid (HA) filler injection on the contralateral side of the periorbital area. Improvements in the visual analog scale and global esthetic improvement scale scores were not significantly different between the PN and HA groups. The improvement rates of skin elasticity and hydration decreased over time in both groups, with the PN group showing a higher improvement rate. The improvement rates of roughness and pore volume were higher in the PN group than in the HA group. The improvement rate of dermal density was not significantly different between the groups. No serious adverse events were reported. The PN filler injection is effective and safe for periorbital rejuvenation. [ABSTRACT FROM AUTHOR]

Background: There are limited data regarding the difference in progression pattern between acral melanoma and nonacral melanoma.Aims: The objectives of this study were to compare the progression pattern between acral and nonacral melanoma and evaluate its impact on clinical outcomes.Methods: Clinical and histopathological features, survival outcomes and prognostic factors of 492 patients with acral melanoma or nonacral melanoma were retrospectively evaluated using the Asan Medical Center database.Results: The male-to-female ratio and the mean age was 1:0.92 and 60.2 years for acral melanoma (n = 249), and 1:0.85 and 58.4 years for nonacral melanoma (n = 243), respectively. The demographic difference was not significant. Although prediagnosis duration was longer and the advanced stage was more common in acral melanoma than that in nonacral melanoma, the vertical growth phase was more common in nonacral melanoma than that in acral melanoma, whereas, the horizontal diameter is longer in acral melanoma than that in nonacral melanoma. Dissemination to lymph nodes was more common in acral melanoma than that in nonacral melanoma. Lymph node involvement was associated with deeper Breslow thickness in nonacral melanoma but not in acral melanoma. The degree of correlation of prediagnosis duration with horizontal diameter was remarkable in acral melanoma, but with Breslow thickness in nonacral melanoma. Overall survival was worse in acral melanoma than that in nonacral melanoma. The prognostic value of Breslow thickness was more remarkable in nonacral melanoma than that in acral melanoma.Limitations: This study is a retrospective, single-center design.Conclusion: Acral melanoma has a longer radial growth phase compared with nonacral melanoma. However, acral melanoma is commonly associated with lymph node dissemination which contributed to worse survival in acral melanoma than nonacral melanoma. [ABSTRACT FROM AUTHOR]

Background: Multiple types of fillers have been developed for soft tissue augmentation. Objective: We investigated the efficacy and safety of the novel filler BM-PHA. Methods: In this multicenter, randomized, split-face study, 91 participants received injections of BM-PHA and Restylane Perlane (PER) into the nasolabial folds. Efficacy was determined by the improvements in the Wrinkle Severity Rating Score (WSRS) and Global Esthetic Improvement Scale (GAIS), and safety by adverse events, laboratory tests, and a check of vital signs. Results: WSRS scores assessed by independent evaluators at Week 24, the primary efficacy measure, showed no significant difference between the two treatments. The treatments also showed no significant differences in WSRS scores assessed by the evaluators at Week 8 and WSRS and GAIS scores assessed by the treating investigators and participants at Weeks 8 and 24. The proportion of nasolabial folds whose WSRS scores improved by at least one grade at Week 24 was similar between the treatments. Only minor local side effects were reported without sequelae. Conclusion: BM-PHA was not inferior to PER in the treatment of moderate to severe nasolabial folds and may be an appropriate alternative product for their improvement. Further studies are needed to confirm the long-term safety of BM-PHA. [ABSTRACT FROM AUTHOR]

Background: Kaposi sarcoma (KS) is a mesenchymal tumor with distinct histopathological features according to stage of progression. Programmed death‐1 (PD‐1) and its ligand PD‐L1 play major roles in the immune escape strategy of tumors. Objectives: This study evaluated expression of PD‐1 and PD‐L1 in various stages of KS and investigated associations between their expression and clinical characteristics. Methods: Fifty cases with histopathologically diagnosed KS were classified as early or late stage. These specimens were stained with anti‐PD‐1 and anti‐PD‐L1 antibodies. The extent of expression in the intratumoral and peritumoral areas was judged by two dermatopathologists. Results: PD‐1 and PD‐L1 were expressed in 72.2% (13/18) and 11.1% (2/18) of early‐stage cases, respectively, compared with 43.8% (14/32) and 28.1% (9/32) of late‐stage cases, respectively. At the late stage, PD‐1 expression was significantly higher in the peritumoral area than in the intratumoral area (P = 0.001). PD‐1 expression in the intratumoral area was significantly higher at the early stage than at the late stage (P = 0.013). PD‐L1 expression in the peritumoral area was significantly higher at the late stage than at the early stage (P = 0.038). Conclusions: The pattern of PD‐1 and PD‐L1 expression differs according to the stage of KS, but is unaffected by clinical variables. [ABSTRACT FROM AUTHOR]

Background: There have been few studies using hyaluronic acid fillers to restore mid‐face volume deficit especially in Asians. Aims: This study compared the efficacy and safety of two highly cohesive hyaluronic acid fillers, Neuramis® Volume Lidocaine and Juvederm® Voluma® with Lidocaine (VYC‐20L), for temporary restoration of mid‐face volume in Asians. Patients/Methods: A total of 88 subjects with moderate to severe age‐related mid‐face volume deficit on the Mid‐Face Volume Deficit Scale (MFVDS) received Neuramis® Volume Lidocaine on one side and VYC‐20L on the other side of the face. Response was defined as a ≥1 point reduction in MFVDS at 24 weeks after the injection by photographic assessment. Secondary end points included photographic and live assessments of MFVDS and its changes at week 4, 12, and 24; global aesthetic improvements, as assessed by the investigators and the subjects at each visit; and the proportion of subjects who received touch‐up treatment. Results: The response rates of the sides treated with Neuramis® Volume Lidocaine and VYC‐20L were identical (96.39%) at week 24, demonstrating that Neuramis® Volume Lidocaine was noninferior to VYC‐20L. Photographic and live assessments of MFVDS and its changes, global aesthetic improvement, and the proportion of subjects who received touch‐up treatment did not differ significantly during follow‐up. Conclusions: Neuramis® Volume Lidocaine was not inferior to VYC‐20L in temporarily restoring mid‐face volume at 24 weeks after treatment. Both of these highly cohesive hyaluronic acid fillers can be used effectively and safely for the correction of mid‐face volume loss in Asians. [ABSTRACT FROM AUTHOR]

A total of 272 070 patients with internal malignancies were identified; 401 patients with cutaneous metastasis were included. However, in the current study, only 0.15% of patients developed skin metastases, which may reflect that regular health checks are common in Korea and that only patients who underwent skin biopsy were included. Lesions were identified in more than one location in 63 patients; 39.0% of cutaneous metastases were located in the chest, and the majority were metastases from breast cancers (84.4% of chest lesions). GRAPH: Table S1 Underlying primary cancers in patients with cutaneous metastases according to anatomical locationTable S2 Mean time to metastasis according to sex and primary cancer. [Extracted from the article]